Icon

SUBVENITE (NDA218879)- (10MG/ML)

LAMOTRIGINE OWP PHARMS
10MG/ML
No Yes
2040-May-29 Expired
None None
None No
SUBVENITE is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures • primary generalized tonic-clonic (PGTC) seizures • generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy.
0 0 0
Total Other Developers 1
Drugs with Suitability No
10MG/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.